Curing Diabetes with Innovative Targeted Therapy
Pharmasaga is developing PS-001, the world's first small-molecule new drug of its kind, which effectively inhibits the PDIA4 protein to prevent beta-cell death — bringing new hope for a cure to patients with type 2 diabetes.
A Breakthrough Diabetes Treatment Platform
Our research team was the first to discover and identify the novel diabetes target PDIA4, and used a molecular docking technology platform to identify lead compounds that inhibit PDIA4 — developing PS-001, a potential first-in-class small-molecule new drug for the diabetes market.
About Pharmasaga
PharmasagaPharmasaga was founded in January 2021 as a spin-off company from Academia Sinica, licensing PS1, the research achievement of over a decade of work in Dr. Wen-Chin Yang's laboratory. PS1 effectively inhibits PDIA4, a protein that plays a key role in diabetes, and data shows it can prevent beta-cell death and stabilize blood sugar.
Latest News
PS-001 Clinical Trial — Now Recruiting Subjects
Age 18-80 · BMI 18.5-40 · HbA1c 5.7-9.0% · Conducted by Taipei Medical University Hospital
Careers
Join us and help
rewrite the future of diabetes treatment
Pharmasaga welcomes those passionate about new drug development to join us. From molecular biology to clinical development, together we bring breakthroughs to patients worldwide.
View All Openings →R&D / Clinical Scientist
Participate in PS-001 clinical trial design and data analysis, in partnership with the Taipei Medical University team
Regulatory & Business Development
Responsible for international licensing partnerships, regulatory submission documents, and investor communications
Internships & Graduate Programs
Internship opportunities for students in biotech-related fields, cultivating the next generation of R&D talent
Investors
Financial Information
Annual reports, quarterly
reports & operating data
Shareholders
Shareholder meeting notices
& proceedings downloads
Corporate Governance
Board of directors, governance
charter & internal controls
Investor Conferences
Session schedule &
presentation downloads
Interested in investment
opportunities at Pharmasaga?
Contact our Investor Relations team for the latest financial data, investor conference information, or to subscribe to announcement updates.
Contact Information
Address
22F-1, No. 93, Sec. 1, Xintai 5th Rd.,
Xizhi Dist., New Taipei City 221416, Taiwan
Phone
+886-2-27938665
contact@pharmasaga.com
Public Transit
TRA Xike Station
or bus to Dongfang Science Park